Y-mAbs Announces Data to be Presented at SIOP 2021
Retrieved on:
Thursday, September 16, 2021
Neuropathic pain, MSK, 2021 Essex County Council election, Anaphylaxis, Therapy, Government, Osteosarcoma, Private Securities Litigation Reform Act, FDA, Cardiac arrest, Neuroblastoma, Diffuse intrinsic pontine glioma, Neurotoxicity, Coronavirus, Failure, Marketing, Patient, International Society, Company, Pinealoblastoma, Neoplasm, Safety, Adult, Annual report, Industry, Cancer, Hospital, NASDAQ, Growth, COVID-19, Memorial Sloan Kettering Cancer Center, Ependymoma, Medulloblastoma, Transverse myelitis, CNS, GLOBE, Granulocyte-macrophage colony-stimulating factor, Risk, GD2, SEC, Research, Bone marrow, Congress, Pharmaceutical industry, Medical imaging
As a result of this licensing arrangement, MSK has institutional financial interests in the compounds.
Key Points:
- As a result of this licensing arrangement, MSK has institutional financial interests in the compounds.
- This indication was approved under accelerated approval based on overall response rate and duration of response.
- Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial.
- Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.